Acrivon Therapeutics (ACRV) EPS (Basic) (2021 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly EPS (Basic) of -$0.58 for Q1 2026, up 12.95% year-over-year from -$0.51 in Q1 2025, and down 5.76% quarter-over-quarter from -$0.55 in Q4 2025.
Acrivon Therapeutics (ACRV) EPS (Basic) (2021 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported EPS (Basic) for 6 consecutive years, with -$0.58 the latest figure, recorded in Q1 2026.
- In Q1 2026, EPS (Basic) rose 12.95% year-over-year to -$0.58; the TTM figure through Mar 2026 stood at -$2.24 (up 22.59% YoY), while the FY2025 annual figure was -$2.22, up 48.61% from the prior year.
- EPS (Basic) eased to -$0.58 in Q1 2026 per ACRV's latest filing, from -$0.55 in the prior quarter.
- Across five years, EPS (Basic) topped out at -$0.52 in Q3 2025 and bottomed at -$8.96 in Q3 2022.
- Historically, EPS (Basic) has averaged -$1.81 across 5 years, with a median of -$0.97 in 2023.
- Annual changes were most pronounced in 2022 — EPS (Basic) plunged 493.42% — and 2023, when it jumped 85.7%.
- Acrivon Therapeutics' EPS (Basic) stood at -$2.49 in 2022, then soared by 61.09% to -$0.97 in 2023, then advanced by 22.12% to -$0.75 in 2024, then climbed by 27.03% to -$0.55 in 2025, then fell by 5.76% to -$0.58 in 2026.
- Business Quant data shows ACRV's EPS (Basic) at -$0.58 in Q1 2026, -$0.55 in Q4 2025, and -$0.52 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | 7.59 |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | -1.96 |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 2.12 |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 1.23 |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | -0.72 |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | -0.06 |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 0.18 |
| 10 | Acrivon Therapeutics | 96.03 Mn | 96.03 Mn | - | -0.43 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.54 |
| Mar 31, 2026 | -0.58 |
| Dec 31, 2025 | -0.55 |
| Sep 30, 2025 | -0.52 |
| Jun 30, 2025 | -0.60 |
| Mar 31, 2025 | -0.67 |
| Dec 31, 2024 | -0.75 |
| Sep 30, 2024 | -0.88 |
| Jun 30, 2024 | -0.73 |
| Mar 31, 2024 | -1.20 |
| Dec 31, 2023 | -0.97 |
| Sep 30, 2023 | -1.28 |
| Jun 30, 2023 | -1.59 |
| Mar 31, 2023 | -1.60 |
| Dec 31, 2022 | -2.49 |
| Sep 30, 2022 | -8.96 |
| Jun 30, 2022 | -3.35 |
| Mar 31, 2022 | -4.08 |
| Dec 31, 2021 | -3.60 |
| Sep 30, 2021 | -1.51 |